---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024737"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:53:28.513380+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tivic Health Q3 revenue up 72% to $477K; net loss $2.6M; agrees to acquire Reliefband for $33.5M

## Summary
- Q3 2022 revenue $477K (+72% YoY); DTC unit sales up 130%; gross margin improved 22%.
- Net loss $2.6M vs $2.3M in Q3 2021; cash and short-term investments $6.3M at Sept 30, 2022.
- Entered asset purchase agreement for Reliefband (nausea treatment devices) for $33.5M cash; expected close Q4 2022/Q1 2023.
- Manufacturing agreement with Microart to reduce ClearUP production costs; MSRP increased $20/unit.

## SEC filing metadata
- accession: 0000950170-22-024737
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000095017022024737/0000950170-22-024737-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000095017022024737/tivc-20221114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024737
- JSON: https://secwatch.observer/filing/0000950170-22-024737.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024737.txt

## Key facts
- Earnings Releases
  Valion Bio, Inc. reported the quarter ended September 30, 2022 results: revenue $477 thousand, net income $2.6 million.
  - Period: the quarter ended September 30, 2022
  - Revenue: $477 thousand
  - Net income: $2.6 million
  - Result: reported results
  source text: Third Quarter 2022 Financial Highlights (as compared to the same periods in 2021) For the three months ended September 30, 2022: • Revenue increased 72% from $277 thousand to $477 thousand
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787740/000095017022024737/0000950170-22-024737-index.htm
- Earnings Releases
  Valion Bio, Inc. reported the nine months ended September 30, 2022 results: revenue $1.4 million.
  - Period: the nine months ended September 30, 2022
  - Revenue: $1.4 million
  - Result: reported results
  source text: For the nine months ended September 30, 2022: • Revenue increased $65% from $868 thousand to $1.4 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787740/000095017022024737/0000950170-22-024737-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.